Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

Por Goltsov, Alexey, Deeni, Yusuf, Khalil, Hilal S., Soininen, Tero, Kyriakidis, Stylianos, Hu, Huizhong, Langdon, Simon P., Harrison, David J., Bown, James
Publicado em 2014

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Por Canfield, Kaleigh, Li, Jiaqi, Wilkins, Owen M., Morrison, Meghan M, Ung, Matthew, Wells, Wendy, Williams, Charlotte R., Liby, Karen T, Vullhorst, Detlef, Buonanno, Andres, Hu, Huizhong, Schiff, Rachel, Cook, Rebecca S, Kurokawa, Manabu
Publicado no Cell Cycle (2015)

Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy

Por Giuliano, Mario, Hu, Huizhong, Wang, Yen-Chao, Fu, Xiaoyong, Nardone, Agostina, Herrera, Sabrina, Mao, Sufeng, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Hilsenbeck, Susan G., De Angelis, Carmine, Wang, Nicholas J., Heiser, Laura M., Gray, Joe W., Lopez-Tarruella, Sara, Pavlick, Anne C., Trivedi, Meghana V., Chamness, Gary C., Chang, Jenny C., Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Publicado no Clin Cancer Res (2015)